Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 21% of the time (1,462 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-12-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalequal toactivegreater thancell
  Phrases that lowered it: screeningdrugspharmacokineticsthe studyinclusive
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 1/2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 590 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 5.9% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 53 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 80 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001 NCT03126318 · started 2017 · scored riskier than 40% of active trials completed
• Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide NCT01043146 · started 2009 · scored riskier than 2% of active trials completed
• Study of COR388 HCl in Healthy Subjects NCT03331900 · started 2017 · scored riskier than 5% of active trials completed
• A Single and Multiple Ascending Dose Study of COR588 NCT04920903 · started 2021 · scored riskier than 8% of active trials completed
• Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) NCT03400033 · started 2018 · scored riskier than 74% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.